Atara Biotherapeutics

^{Priced, Nasdaq: ATRA}

Early-stage biotech targeting muscle loss in patients with end-stage renal disease.

Industry: Health Care

First Day Return: -3.2%

ATRA

Early-stage biotech targeting muscle loss in patients with end-stage renal disease.

IPO News for Atara Biotherapeutics

US IPO Weekly Recap: 5 IPOs achieve moderate gains during the market slide and a biotech rejection 10/17/14
Atara Biotherapeutics prices IPO at $11, below the range 10/16/14
7 US IPOs planned for the week of October 13, including the IPO market's biotech test 10/12/14

IPO Data
IPO Date	10/15/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$55
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.atarabio.com
Headquarters	Brisbane, CA, United States
Founded	2012
Employees at IPO	15

IPO News for Atara Biotherapeutics

Atara Biotherapeutics (ATRA) Performance